Payment overview · 2025
General Payments
$539.24
17 reported records · 7 companies
Healthcare provider profile · identity verified
Barbara Caciolo, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · ST LOUIS, MO · NPI 1861582298
Verified facts
What the public records show
CMS Open Payments records show Barbara Caciolo, MD received $539.24 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 50.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Enbrel, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Enbrel by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $274.68 | 50.9% | 9 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $116.33 | 21.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.68 | 9.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.28 | 6.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.54 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.77 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.96 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $539.24 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $135.52 | 8 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $116.33 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $104.77 | 6 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $52.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENBREL enbrel |
2025 | Enbrel | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 243 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 58 |
| Lisinopril | Lisinopril | 196 | 53 |
| Methotrexate | Methotrexate Sodium | 193 | 54 |
| Metformin Hcl | Metformin Hcl | 180 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 144 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 39 |
| Allopurinol | Allopurinol | 137 | 35 |
| Losartan Potassium | Losartan Potassium | 137 | 41 |
| Furosemide | Furosemide | 123 | 36 |
| Gabapentin | Gabapentin | 114 | 36 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 113 | 31 |
| Prednisone | Prednisone | 110 | 59 |
| Valsartan | Valsartan | 102 | 30 |
| Montelukast Sodium | Montelukast Sodium | 100 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 97 | 28 |
| Simvastatin | Simvastatin | 89 | 23 |
| Omeprazole | Omeprazole | 88 | 23 |
| Meloxicam | Meloxicam | 77 | 25 |
| Potassium Chloride | Potassium Chloride | 77 | 21 |
| Folic Acid | Folic Acid | 76 | 21 |
| Eliquis | Apixaban | 73 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 68 | 16 |
| Leflunomide | Leflunomide | 67 | 18 |
| Tramadol Hcl | Tramadol Hcl | 66 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 14 |
| Atenolol | Atenolol | 55 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 12 |
| Famotidine | Famotidine | 52 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 16 |
| Azithromycin | Azithromycin | 46 | 40 |
| Alendronate Sodium | Alendronate Sodium | 45 | 12 |
| Buspirone Hcl | Buspirone Hcl | 44 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 14 |
| Lovastatin | Lovastatin | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 13 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | 13 |
| Sulfasalazine | Sulfasalazine | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | 11 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Ozempic | Semaglutide | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Humira | Adalimumab | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Enbrel Sureclick | Etanercept | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Diazepam | Diazepam | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Carvedilol | Carvedilol | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $539.24 · 17 records | Amgen Inc. | ENBREL, GLASSIA, OTEZLA, Ozempic, RINVOQ, Rybelsus, SAPHNELO, TALTZ, XELJANZ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Enbrel play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error